Use of EGFR / c-met bispecific binding protein

TW202639168APending Publication Date: 2026-10-01SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114151878
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-24
Filing Date
2025-12-30
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001078915_001
    Figure TWG2TA001078915_001
  • Figure TWG2TA001078915_002
    Figure TWG2TA001078915_002
  • Figure TWG2TA001078915_003
    Figure TWG2TA001078915_003
Patent Text Reader

Abstract

Epidermal growth factor receptor / Hepatocyte growth factor receptor (EGFR / c-Met) bispecific antibodies for use in inhibiting EGFR phosphorylation and / or c-Met phosphorylation and as such blocking the EGFR / c-Met downstream signaling pathway.The EGFR / c-Met bispecific antibodies may be used for the prevention, treatment and / or adjuvant treatment of various cancers. In particular, the EGFR / c-Met bispecific antibodies may be used for the prevention, treatment and / or adjuvant treatment of non-small cell lung cancer.
Need to check novelty before this filing date? Find Prior Art